| 摘要 |
Inhibiting bone resorption in a mammal, comprises orally administering bisphosphonate (I) as a unit dosage according to a continuous schedule having a dosing interval selected from once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing. Also claimed are: (A) treatment and prevention of osteoporosis in a mammal comprising orally administering (I) as a unit dosage according to a continuous schedule as above; (B) treatment of abnormal bone resorption in a human comprising orally administering a unit dosage of (I) comprising 17.5-140 mg (on an alendronic acid basis) of (I) selected from alendronate (Ia) and/or its salts; (C) preventing abnormal bone resorption in a human comprising orally administering a unit dosage of (I) comprising 8.75-70 mg (on an alendronic acid active basis) of (I) selected from (Ia) and/or its salts; (D) inhibiting bone resorption in a mammal comprising sequentially orally administering to the mammal a unit dosage of histamine H2 b locker or a proton pump inhibitor and a unit dosage of (I) according to a continuous schedule as above; (E) composition comprising 70 mg (on an alendronic acid active basis) of (I) selected from (Ia) and/or its salts; (F) a kit for inhibiting bone resorption in a mammal comprising at least one unit dosage of (I) for oral administration according to a continuous schedule as above; (G) a method for inhibiting bone resorption in a mammal comprising orally administering to the mammal (I) as a unit dosage according to a continuous schedule having a periodicity from once every 3 days to once every 16 days. |
